Simplify Logo

Full-Time

Director – Quality Assurance Operations

Confirmed live in the last 24 hours

Adicet Bio, Inc

Adicet Bio, Inc

51-200 employees

Develops allogeneic gamma delta T cell therapies

Hardware
Biotechnology
Healthcare

Compensation Overview

$188k - $260kAnnually

Senior, Expert

San Carlos, CA, USA

Category
QA & Testing
Manual Testing
Quality Assurance
Required Skills
Management
Quality Assurance (QA)
Requirements
  • Bachelor’s Degree in scientific or relevant disciplines in life sciences.
  • 10+ years of experience within the life sciences industry, preferably biotechnology, pharmaceuticals, or other regulated therapeutic environment with 6+ years in a Quality Assurance role
  • 5+ years of direct management experience
  • Demonstrated mastery of cGMP regulations and quality systems
  • Thorough knowledge of applicable regulatory requirements (FDA CFR, EMA, ICH, ISO, any other global laws/regulations)
  • Experience with Health Authority Inspections
  • Proficiency with electronic management systems (such as LIMS, eQMS,)
  • Strong interpersonal and communication skills: written and oral.
  • Outstanding planning, organization, and multitasking skills.
  • Travel as required.
Responsibilities
  • Ensure current Good Manufacturing Practices (cGMPs) compliance for clinical manufacturing of phase I/II/III investigational product, and compliance to 21 CFR Parts 210, 211, ICH Guidelines and EU GMPs as applicable.
  • Accountable for lot disposition activities including batch record review, in-process/release and stability testing review, oversight of quality events relating to GMP product, process, or facility, etc. Will lead by example to partner with cross functional groups to meet company objectives in compliance with applicable regulatory guidelines.
  • Review approval of development activities in preparation for GMP such as development studies/reports, engineering activities, etc.
  • Collaborates with cross functional teams and champions the Quality Risk Management Program.
  • Responsible for the phase appropriate validation program.
  • Serves as team leader in quality related discussions, investigations, risk assessments, change controls, etc. to resolve potential product quality issues and to ensure they are appropriately addressed and justified.
  • Partners with Facilities and functional SMEs to support equipment qualifications and lifecycle management.
  • Collaborates with Quality Systems to manage the cGxP training program for internal manufacturing related functions.
  • Represents the organization during third-party audits and inspections as required.
  • Provides technical expertise and guidance in conducting investigations in regard to quality deviations, laboratory investigations/change controls systems for tracking statuses, follow-up, and liaison with applicable department investigation writers to ensure their complete and timely resolution.
  • Provides oversight for the raw material program, including raw material QA release.
  • Develop and implement procedures, programs and policies that support quality assurance functions and assure cGxP compliance.
  • Supports regulatory submissions of quality related sections.
  • Be a champion for continuous improvement. Identifies and drives continuous improvement initiatives and monitors progress of deliverables.
  • Other duties as required.

Adicet Bio develops cancer therapies using allogeneic gamma delta T cell therapies, which are immune cells designed to target and destroy cancer cells. Their approach utilizes donor-derived cells that are readily available, allowing for faster treatment compared to traditional methods that require a patient's own cells. The company focuses on serving healthcare providers, hospitals, and research institutions involved in cancer treatment. Adicet Bio's business model includes developing and commercializing its proprietary therapies, generating revenue through product sales and licensing agreements. A recent merger with resTORbio aims to enhance their technology and accelerate development. With significant funding, Adicet Bio is positioned to improve cancer treatment outcomes through its unique immunotherapy approach.

Company Stage

IPO

Total Funding

$243.6M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

-3%

1 year growth

-1%

2 year growth

39%
Simplify Jobs

Simplify's Take

What believers are saying

  • Adicet Bio's strong financial position, with $247.6 million in cash and cash equivalents, provides a solid foundation for continued R&D and clinical trials.
  • The promising preclinical data on ADI-270 and the initiation of multiple Phase 1 trials highlight the company's robust pipeline and potential for breakthrough therapies.
  • The company's strategic focus on both solid and hematological cancers, as well as autoimmune diseases, increases the likelihood of successful treatments and market adoption.

What critics are saying

  • The clinical and regulatory landscape for new cancer therapies is highly competitive and uncertain, posing risks to Adicet Bio's market entry and adoption.
  • The reliance on successful clinical trial outcomes for ADI-001 and ADI-270 introduces significant uncertainty and potential delays in commercialization.

What makes Adicet Bio, Inc unique

  • Adicet Bio's use of allogeneic gamma delta T cells offers an 'off-the-shelf' solution, providing faster and potentially more effective cancer treatments compared to autologous therapies.
  • The company's focus on both cancer and autoimmune diseases broadens its market reach and potential impact, unlike competitors who may focus solely on one area.
  • Adicet Bio's recent merger with resTORbio and significant funding rounds, including an $80 million Series B, bolster its R&D capabilities and accelerate its path to commercialization.